The purpose of this study was to identify prognostic parameters for patients with follicular lymphoma (FL) in first progression/relapse. These would be useful for selection of high-risk patients for inclusion in trials aimed at determining the effect of new treatment approaches in such patients.
Introduction
The majority of patients with follicular lymphoma (FL) present with disseminated disease and have a relatively indolent course, the median survival being 6-10 years. However, FL is not curable with conventional therapies, and most patients die from causes related to the disease, frequently after having experienced many relapses [1] [2] [3] [4] . Given the above facts, new potentially more effective, but also potentially more toxic, treatments are increasingly being used to treat FL. These include purine analogs, either alone or in combination [5, 6] , monoclonal antibodies [7] [8] [9] , biological agents and stem cell transplantation [10] [11] [12] [13] [14] [15] [16] . Although there is evidence that these approaches can be useful, their exact role and the best timing for such treatments are not yet well established. On the other hand, although the toxicity related to some of these approaches appears to be acceptable [7, 17] , the complications caused by other strategies are of concern. For example, the incidence of myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) after stem cell transplantation has been found to be 4-12% [14, 15, 18] . Taking all these facts into account, as well as the responsiveness of the disease to standard treatments and its rather indolent nature, experimental treatments are usually reserved for patients in relapse. Therefore, the analysis of prognostic factors at relapse should be useful to select patients for whom inclusion in experimental trials is warranted.
The aim of the present study was to analyze the prognostic features in a series of patients with FL from a single institution, focusing on the variables at the time of the first relapse or progression that predict survival.
Patients and methods

Initial characteristics and treatment
Two-hundred-and-one patients (median age 54 years; 107 males, 94 females) consecutively diagnosed with FL between January 1977 and December 1997 in a single institution were the basis for this study. The histological distribution according to the Revised European-American Classification of Lymphoid Neoplasms/World Health Organization (REAL/WHO) classification [19, 20] Initial treatment consisted of: monotherapy with alkylating agents, 29 patients (14%); COP chemotherapy (cyclophosphamide, vincristine and prednisone), 28 patients (14%); adriamycin-containing regimens (in most cases CHOP: cyclophosphamide, adriamycin, vincristine and prednisone), 126 patients (63%); and other treatments, 18 patients.
Among 191 assessable patients, 87 (46%) attained a complete response (CR), 77 (40%) a partial response (PR), while 27 patients (14%) were considered non-responders. After a median follow-up of 4.5 years, 41 of the 87 CR patients (47%) and 49 of 77 PR patients (64%) had progressed. Overall, the median response duration (RD) was 2.3 years. These 90 patients (48 male, 42 female; median age 56 years) who responded to treatment and eventually relapsed/progressed were the subject of the present study. The main characteristics at diagnosis and relapse are listed in Table 1 .
Staging, evaluation at response and follow-up procedures
Initial staging procedures included computed tomography of the thorax, abdomen and pelvis, as well as a bone marrow biopsy. Post-therapy restaging included the repetition of the previously abnormal tests and/or biopsies.
CR was defined as the disappearance of tumor masses and diseaserelated symptoms, as well as the normalization of the initially abnormal tests and/or biopsies, lasting for at least 1 month. PR was considered as measurable lesions decreased by at least 50% [22] . Patients not included in these categories and those who died before completing treatment were considered non-responders.
The follow-up surveillance procedures after treatment consisted of physical examination, blood count tests and biochemistry, and chest X-ray (if initially abnormal) every 3 months during the first year, every 4 months during the second year, every 6 months during the next 3 years and every year afterwards. When the abdomen was the principally involved site, abdominal computer tomography (CT) scans were performed every 6 months during the first year and yearly for the following 5 years. Molecular follow-up was performed only during the last 4 years (1996) (1997) (1998) (1999) (2000) .
At the time of clinical relapse or progression, a new lymph node biopsy was performed whenever possible. However, such a procedure was carried out in only half of the patients due to older age, poor performance status or patient refusal. For the same reasons, a new bone marrow biopsy could only be obtained in 42 patients. In addition, restaging of the patients included CT scans of the thorax, abdomen and pelvis. 
Statistical analysis
Overall survival was defined as the time between the date of diagnosis and the date of last follow-up or death; cause-specific survival, as the date of diagnosis to the date of last follow-up or lymphoma-related death; time to treatment failure (TTF), as the start of treatment to one of the following events: death from any cause, disease progression or relapse, or date of last observation [22] . Survival from progression (SFP) for responding patients (CR or PR) was defined as the time from relapse or progression to the date of last follow-up or death [23] . Cause-specific SFP for responding patients (CR or PR) was defined as the time from relapse or progression to the date of last follow-up or lymphoma-related death.
The main end point of the study was SFP. In addition, TTF and overall survival were analyzed. Actuarial survival analysis was performed according to the method described by Kaplan and Meier [24] , and the curves compared by the log-rank test [25] . The univariate analysis was carried out for each of the parameters indicated above. All significant prognostic factors in the univariate study were included in a multivariate analysis performed by Cox's stepwise proportional hazard regression method [26] .
Results
Time to treatment failure and overall survival in the whole series TTF in the overall series (201 patients) is plotted in Figure 1 . Five-year TTF was 42% [95% confidence interval (CI) 34% to 49%].
Seventy-two patients died during the follow-up period. The median overall survival was 9.3 years, and the 5-year and 10-year overall survival were 71% (95% CI 65% to 76%) and 48% (95% CI 39% to 57%), respectively ( Figure 1 ). Eleven patients (15%) died from non-lymphoma-related causes, with a median cause-specific survival of 14.3 years.
Characteristics of the patients at progression, salvage therapy and response
Of 164 responders, 90 (55%) presented with disease progression or relapse during the follow-up period. These patients had been registered from January 1976 to August 1997, with a median follow-up for alive patients of 6.25 years (range 2.1-21.6 years). The median age at progression was 56 years (range 26-78 years). The most important characteristics of these patients both at diagnosis and at progression are listed in Table 1 . Among 82 assessable patients, 55 (67%) were in advanced stage and 35 (42%) had an intermediate-or highrisk prognosis, according to the IPI. Among 45 rebiopsed patients, histological transformation into a high-grade lymphoma was observed in nine cases (20%) (diffuse large-cell lymphoma in all of these). Patients in whom a new biopsy was not performed were older than those rebiopsed (patients ≥65 years, 33% versus 13%, respectively; P = 0.04). Treatment at progression varied during the study period and consisted of: monotherapy with alkylating agents, 27 patients (30%); combination chemotherapy, 40 patients (45%); fludarabine alone or in combination, 12 patients (13%); and other treatments, 11 patients (12%) including only radiotherapy in three stage I patients. In addition, stem cell transplantation was performed in seven cases as part of the salvage treatment. In the subset of nine patients, in whom histological transformation was diagnosed, combination chemotherapy was given in all the cases, followed by autologous stem cell transplantation in four cases. Thirty-four (41%) of 83 assessable patients had a CR, 29 (35%) a PR, while 20 patients (24%) were considered as nonresponders.
Survival from progression
The median SFP was 4.8 years, with a 5-year SFP of 47% (95% CI 35% to 58%) (Figure 2) . The most important variables predicting SFP are detailed in Table 2 . As indicated, advanced stage at diagnosis was the only initial factor retaining predictive value for SFP. First-line therapy did not influence SFP. In the univariate analysis, unfavorable prognostic factors at progression were bulky disease, poor performance status, high serum LDH level, high serum β2M, bone marrow involvement, advanced stage, intermediate-or high-risk IPI, and an RD <2 years. Older age (≥60 years) showed a trend for statistical significance. Regarding salvage therapy, there were no differences in SFP according to the salvage regimen used, including ASCT. There was a trend for a higher SFP in patients receiving fludarabine combinations (P = 0.09), but these patients were highly selected in terms of age, performance status and follow-up. A relatively high number of missing data was found for four of these variables (LDH, β2M, bone marrow involvement and transformation). We analyzed the SFP for patients with known data versus those with missing data. Patients with unknown LDH, bone marrow or lymph node biopsy had a worse SFP than the others, whereas no significant differences were found for β2M (data not shown). The SFP according to the RD is shown in Figure 3 . When the same analysis was performed in the subset of patients in advanced stage at progression, no significant differences were found according to the RD [5-year SFP: 21% (95% CI 0% to 44%) and 45% (95% CI 19% to 70%) for RD <2 and RD ≥2 years, respectively; P = not significant]. In the subgroup of patients in localized stage, the RD maintained its prognostic significance with a 5-year SFP of 38% (95% CI 7% to 69%) in patients with a RD <2 years and a 5-year SFP of 92% (95% CI 78% to 100%) in patients with a longer RD (P = 0.013). When RD and stage were compared by a Cox regression, only stage retained prognostic significance for SFP [P = 0.015, relative risk (RR) 2.9 (95% CI 1.2-6.8)]. The univariate analysis was carried out for the subgroup of patients <60 years old, with this showing the same prognostic factors for SFP (data not shown). On the other hand, among the 45 patients in whom a new lymph node biopsy was obtained, no differences in survival were found according to the histological transformation event [5-year SFP 63% (95% CI 44% to 82%) and 62% (95% CI 29% to 95%) for transformed and non-transformed patients, respectively]. Non-biopsed patients had a shorter SFP than biopsed patients [5-year SFP 32% (95% CI 16% to 48%) versus 62% (95% CI 46% to 78%); P = 0.004].
For the multivariate analysis all the variables with prognostic significance in the univariate study (P value <0.1) and with a sufficient number of assessable cases were selected. As a result, LDH level, β2M level, bone marrow involvement and the histology at relapse were not included. On the other hand, response to initial treatment (CR versus PR) was included, due to its clinical interest. Finally, a multivariate analysis was performed including stage at diagnosis (I-II versus III-IV), initial clinical response (CR versus PR), age at relapse (continuous variable), stage at relapse (I-II versus III-IV), bulky disease at relapse, performance status at relapse (ECOG <2 versus ECOG ≥2) and RD (<2 versus ≥2 years). Seventy-nine of the 90 study patients were included in the final multivariate analysis for SFP. The factors retaining prognostic importance for SFP were: RD [P = 0.011, RR 0.37 (95% CI 0.17-0.8)] and poor performance status at progression [P <0.001, RR 9.0 (95% CI 3.6-22)]. As can be observed in Figure 4 , only 10 of the 33 patients with ECOG <2 and RD ≥2 died during the follow-up, with a 5-year SFP of 68% (95% CI 50% to 86%). Five-year SFP was 36% (95% CI 16% to 56%) for those patients having one of the two unfavorable variables, and 0% for those presenting the two unfavorable variables. Finally, in order to assess the prognostic value of the IPI in the setting of relapsed patients, we performed the multivariate analysis including the IPI at relapse, along with the above-mentioned variables. Poor performance status at progression [P = 0.0008; RR 5.09 (95% CI 1.9-13.3)], intermediate-or high-risk IPI at progression [P = 0.025; RR 2.5 (95% CI 1.1-5.5)] and an RD <2 years [P = 0.02; RR 2.4 (95% CI 1.14-5.3)] retained prognostic value for SFP when we included IPI at relapse in the multivariate analysis. In the subgroup of patients <60 years old, the multivariate analysis showed that performance status (P <0.001) and RD (P = 0.01), in addition to bulky disease at progression (P = 0.001), were the most important features for predicting SFP.
Cause-specific survival from progression
Thirty-nine of 90 relapsed patients died from lymphoma, whereas three patients died from non-lymphoma related causes. Five-year cause-specific SFP was 48% (95% CI 36% to 60%) (Figure 2) . A multivariate analysis was carried out following the above criteria. Performance status at relapse [P = 0.002; RR 5.1 (95% CI 1.8-14.1)] and RD [P = 0.04; RR 0.4 (95% CI 0.2-0.9)] emerged as the most important variables to predict cause-specific SFP. Survival from progression (SFP) and cause-specific survival from progression (cause-specific SFP) in 90 responding patients who eventually progressed. Five-year SFP: 47% (95% CI 35% to 58%). Five-year cause-specific SFP 48% (95% CI 36% to 60%). 
Discussion
FL is among the most frequent forms of lymphomas in Western countries, where it accounts for 22% of all lymphomas. The median age of the patients at diagnosis was 59 years and the prognosis extremely variable, the median survival in recent series being up to 10 years [1] [2] [3] [4] 27] . FL is incurable with standard therapies. The prognostic factors for patients with FL at diagnosis have been extensively investigated. Thus, older age, poor performance status, advanced stage, bulky disease, leukemic expression, high serum LDH and β2M levels, and a high risk according to the IPI have consistently been found to be associated with a poor outcome [1, 2, [28] [29] [30] [31] [32] [33] [34] [35] . The prognostic significance of many of these variables (i.e. age, stage and LDH) has been confirmed in our series (data not shown).
The natural history of FL is characterized by continuous relapses that become progressively less sensitive to chemotherapy [1] . Although patients with relapsed FL often still respond to further therapy, the RD becomes shorter after each relapse [1] and most patients die due to the disease. All of the above make the management of these patients challenging, with a wide variety of treatment options ranging from a watchful waiting policy to intensive therapies [10] [11] [12] [13] [14] [15] [16] [36] [37] [38] [39] [40] [41] [42] .
New therapeutic approaches are being developed and investigated. These include purine analogs alone or in combination [5, 6] , monoclonal antibodies [7] [8] [9] , high-dose therapy followed by autologous or allogeneic stem-cell transplantation [10] [11] [12] [13] [14] [15] [16] , as well as different biological response modifiers. Preliminary data in selected patients receiving intensive regimens indicate that CR rates are high (up to 90%) and that such responses may be maintained for long periods [5, 11, 16] . However, no differences in terms of survival between conventional and more intensive treatments have been found [10] . Whereas experimental therapies are rarely used at diagnosis, with the exception of investigational trials, such approaches, particularly autologous stem cell transplantation, are increasingly being offered to patients in disease progression [10] [11] [12] [13] [14] [15] [16] . However, patients in whom the disease progresses may still have a relatively long survival with conventional management [1] . On the other hand, the morbidity with some of the new therapies can be high and their long-term toxicity is still largely unknown. This is particularly true with autologous stem-cell transplants, which have been associated in recent analysis with an incidence of MDS/AML ranging from 4 to 12% [14, 15, 18] . Given all these facts, the analysis of prognostic factors at the time of the first relapse or progression could be useful in identifying those patients in whom, due to their extremely poor prognosis, experimental therapies are warranted.
Whereas the prognostic variables of patients with FL at diagnosis have been largely investigated [1, 2, [28] [29] [30] [31] [32] [33] [34] [35] , the prognosis of patients in relapse or progression has been less studied. Advanced age, presence of B-symptoms, anemia and extensive extranodal involvement have been identified as unfavorable clinical characteristics for survival after progression [23, 43, 44] . In the present study, some clinical characteristics at relapse (stage, bulky, performance status and IPI) showed their prognostic value for SFP. Age, although showing a trend for statistical significance, did not reach prognostic value in the multivariate analysis. In fact, the median age in the present series is slightly lower than in others [1, 27, 42] . The number of previous therapies has also been found to be an important factor to predict survival [43, 44] . Finally, other studies [23, 45] showed the importance of the response to the initial therapy and its duration, as well as the response to salvage therapy in the survival of the patients. The prognostic impact of RD, a variable of well known importance in largecell lymphoma as well as in other malignancies [46, 47] , has only been investigated in a few studies. Weisdorf et al. [23] found age at relapse <60 years, CR and a RD >1 year to be associated with a longer survival after progression (5-year Survival from progression according to performance status (ECOG) and the response duration (RD) (P <0.00001). Five-year SFP 68% (95% CI 50% to 86%), 36% (95% CI 16% to 56%) and 0%, for patients with ECOG <2 and RD ≥2, ECOG ≥2 or RD <2, and patients with ECOG ≥2 and RD <2, respectively. SFP was 43% for patients with a RD ≥1 year, whereas it was 28% for patients with a shorter RD; P = 0.0002). In this study, however, no features at relapse, apart from age, were analyzed. Regarding salvage therapy, although there was a trend for a higher SFP among patients who received fludarabine combinations, these patients were younger and their follow-up shorter than the others. On the other hand, molecular response has also been demonstrated to correlate with outcome in FL patients [48] , but this is rarely applicable in routine clinical practice. Moreover, the prognostic importance of molecular follow-up in FL patients is not yet well established.
One limitation of our study, as well as of other studies dealing with patients at relapse, is the difficulty in performing an adequate staging at the moment of relapse or progression. For instance, in our series a bone marrow biopsy was repeated in only 42 of 90 patients. This could lead to relative downstaging of the patients and, subsequently, to decreased IPI scores. Similarly, a new lymph node biopsy to rule out transformation into a high-grade lymphoma was performed in just half of the patients. The main reasons for this were the older age and poor performance status of some patients (inviting us to spare such procedures) and patient's refusal in some cases. Therefore, although we did not find differences among transformed and non-transformed patients, the lack of adverse impact on SFP of histological transformation is most likely due to the low number of cases, and no firm conclusions can be drawn in this regard. On the other hand, those patients in whom no lymph node or bone marrow biopsies or LDH determination were performed showed an unfavorable SFP; this stresses that these procedures were omitted in older patients with poor performance status.
In the present study, RD emerged as an important prognostic factor, with a 5-year SFP ranging from 33% (RD <2 years) to 63% (RD ≥2 years); this cut-off was chosen because it was close to the median RD (2.3 years) (Figure 3 ). In the multivariate analysis, poor performance status at relapse along with RD retained prognostic significance for survival. The same variables, as well as bulky disease at relapse retained prognostic significance for survival in the subset of younger (<60 years) patients. This indicates that not only the RD, but also clinical characteristics at progression, are critical to determining the outcome for these patients. Interestingly, patients with no unfavorable variables (ambulatory performance status and RD ≥2 years) had an excellent outcome after progression with a 5-year survival of 68%. These patients should probably not be considered for experimental treatments, particularly those that are potentially toxic. On the other hand, the median SFP of those patients with any risk factor is <5 years and therefore they may be candidates for experimental and intensive regimens. Of note, the degree of response to first-line therapy (CR versus PR) had only marginal significance in the multivariate analysis both in the whole series and in the group of patients <60 years of age. However, this is in contrast to another study, in which RD and features at relapse were not analyzed together [23] .
In conclusion, clinical characteristics at progression, as well as the duration of first response to therapy, are factors that can be useful to select patients with FL as candidates for experimental therapies and to determine the most appropriate timing for such procedures.
